Promoted Content
Promoted Content

Find Approved Musculoskeletal Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothOffering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

            Contact the Supplier

            Lead Product(s): Succinylcholine Chloride

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 12, 2020

            Details:

            Dr. Reddy's Laboratories has launched Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the USFDA.

            Virtual BoothOur shared vision is to have a World, free of Pain.

            Contact the Supplier

            Lead Product(s): Teriparatide

            Therapeutic Area: Musculoskeletal Product Name: Tetridar

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 18, 2020

            Details:

            Grünenthal and Teva have reached an exclusive agreement for the marketing, distribution, and promotion of teriparatide (Tetridar) in the Spanish market.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eldecalcitol

            Therapeutic Area: Musculoskeletal Product Name: Edirol

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Chugai Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination January 22, 2021

            Details:

            Chugai Pharmaceutical and Taisho Pharmaceutical announced termination of the agreement between both companies regarding co-marketing of Edirol® Capsules 0.5 µg and 0.75 µg, a treatment for osteoporosis for which Chugai has a marketing authorization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Teriparatide

            Therapeutic Area: Musculoskeletal Product Name: Livogiva

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 18, 2021

            Details:

            Livogiva is a new presentation of teriparatide, the only bone anabolic treatment for osteoporosis, which has been developed as a pre-filled pen making it easy to use for patients at high risk of fractures.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Celecoxib

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2021

            Details:

            Unichem Laboratories announced that it has received ANDA approval for its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg from the USFDA to market a generic version of CELEBREX® (Celecoxib) Capsules of G.D. Searle LLC, Division of Pfizer Inc.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Onasemnogene abeparvovec-xioi

            Therapeutic Area: Musculoskeletal Product Name: Zolgensma

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Healthcare Royalty Management

            Deal Size: Undisclosed Upfront Cash: $200.0 million

            Deal Type: Agreement December 22, 2020

            Details:

            REGENXBIO will receive $200 million from HCR as an upfront payment in exchange for REGENXBIO's royalty rights from the net sales of Zolgensma. Agreement provides REGENXBIO with significant additional non-dilutive funding to advance RGX-314 and RGX-121.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eldecalcitol

            Therapeutic Area: Musculoskeletal Product Name: Edirol

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 18, 2020

            Details:

            Chugai has obtained regulatory approval for eldecalcitol (product name: Edirol®), an active vitamin D3 derivative created by Chugai from the China National Medical Products Administration (NMPA).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Succinylcholine Chloride

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            Nexus Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dantrolene Sodium

            Therapeutic Area: Musculoskeletal Product Name: Ryanodex

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: JPMorgan Chase Bank

            Deal Size: $160.0 million Upfront Cash: Undisclosed

            Deal Type: Investment September 24, 2020

            Details:

            The accelerated share repurchase program will support Eagle's multiple anticipated and ongoing drug development activities which include RYANODEX franchise, anticipated near-term launch of vasopressin, and three potential oncology launches PEMFEXY, fulvestrant and SM-88.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tolperisone

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 02, 2020

            Details:

            The presentation will highlight results from a double-blind, randomized, placebo-controlled, multicenter phase 3 study evaluating Tolperisone 100 and 200 mg Three Times Daily (TID) for acute muscle spasm of the back.

            PharmaCompass